Enabling dynamic and intelligent workflows for HPC, data analytics, and AI convergence

The evolution of High-Performance Computing (HPC) platforms enables the design and execution of progressively larger and more complex workflow applications in these systems. The complexity comes not only from the number of elements that compose the workflows but also from the type of computations they perform. While traditional HPC workflows target simulations and modelling of physical phenomena, current needs require in addition data analytics (DA) and artificial intelligence (AI) tasks. However, the development of these workflows is hampered by the lack of proper programming models and environments that support the integration of HPC, DA, and AI, as well as the lack of tools to easily deploy and execute the workflows in HPC systems. To progress in this direction, this paper presents use cases where complex workflows are required and investigates the main issues to be addressed for the HPC/DA/AI convergence. Based on this study, the paper identifies the challenges of a new workflow platform to manage complex workflows. Finally, it proposes a development approach for such a workflow platform addressing these challenges in two directions: first, by defining a software stack that provides the functionalities to manage these complex workflows; and second, by proposing the HPC Workflow as a Service (HPCWaaS) paradigm, which leverages the software stack to facilitate the reusability of complex workflows in federated HPC infrastructures. Proposals presented in this work are subject to study and development as part of the EuroHPC eFlows4HPC project.This work has received funding from the European High-Performance Computing Joint Undertaking (JU) under grant agreement No 955558. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and Spain, Germany, France, Italy, Poland, Switzerland and Norway. In Spain, it has received complementary funding from MCIN/AEI/10.13039/501100011033, Spain and the European Union NextGenerationEU/PRTR (contracts PCI2021-121957, PCI2021-121931, PCI2021-121944, and PCI2021-121927). In Germany, it has received complementary funding from the German Federal Ministry of Education and Research (contracts 16HPC016K, 6GPC016K, 16HPC017 and 16HPC018). In France, it has received financial support from Caisse des dépôts et consignations (CDC) under the action PIA ADEIP (project Calculateurs). In Italy, it has been preliminary approved for complimentary funding by Ministero dello Sviluppo Economico (MiSE) (ref. project prop. 2659). In Norway, it has received complementary funding from the Norwegian Research Council, Norway under project number 323825. In Switzerland, it has been preliminary approved for complimentary funding by the State Secretariat for Education, Research, and Innovation (SERI), Norway. In Poland, it is partially supported by the National Centre for Research and Development under decision DWM/EuroHPCJU/4/2021. The authors also acknowledge financial support by MCIN/AEI /10.13039/501100011033, Spain through the “Severo Ochoa Programme for Centres of Excellence in R&D” under Grant CEX2018-000797-S, the Spanish Government, Spain (contract PID2019-107255 GB) and by Generalitat de Catalunya, Spain (contract 2017-SGR-01414). Anna Queralt is a Serra Húnter Fellow.With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2018-000797-S)

Identification of a BRCA2-Specific modifier locus at 6p24 related to breast cancer risk

Common genetic variants contribute to the observed variation in breast cancer risk for BRCA2 mutation carriers; those known to date have all been found through population-based genome-wide association studies (GWAS). To comprehensively identify breast cancer risk modifying loci for BRCA2 mutation carriers, we conducted a deep replication of an ongoing GWAS discovery study. Using the ranked P-values of the breast cancer associations with the imputed genotype of 1.4 M SNPs, 19,029 SNPs were selected and designed for inclusion on a custom Illumina array that included a total of 211,155 SNPs as part of a multi-consortial project. DNA samples from 3,881 breast cancer affected and 4,330 unaffected BRCA2 mutation carriers from 47 studies belonging to the Consortium of Investigators of Modifiers of BRCA1/2 were genotyped and available for analysis. We replicated previously reported breast cancer susceptibility alleles in these BRCA2 mutation carriers and for several regions (including FGFR2, MAP3K1, CDKN2A/B, and PTHLH) identified SNPs that have stronger evidence of association than those previously published. We also identified a novel susceptibility allele at 6p24 that was inversely associated with risk in BRCA2 mutation carriers (rs9348512; per allele HR = 0.85, 95% CI 0.80-0.90, P = 3.9×10−8). This SNP was not associated with breast cancer risk either in the general population or in BRCA1 mutation carriers. The locus lies within a region containing TFAP2A, which encodes a transcriptional activation protein that interacts with several tumor suppressor genes. This report identifies the first breast cancer risk locus specific to a BRCA2 mutation background. This comprehensive update of novel and previously reported breast cancer susceptibility loci contributes to the establishment of a panel of SNPs that modify breast cancer risk in BRCA2 mutation carriers. This panel may have clinical utility for women with BRCA2 mutations weighing options for medical prevention of breast cancer

The spotted gar genome illuminates vertebrate evolution and facilitates human-teleost comparisons

To connect human biology to fish biomedical models, we sequenced the genome of spotted gar (Lepisosteus oculatus), whose lineage diverged from teleosts before teleost genome duplication (TGD). The slowly evolving gar genome has conserved in content and size many entire chromosomes from bony vertebrate ancestors. Gar bridges teleosts to tetrapods by illuminating the evolution of immunity, mineralization and development (mediated, for example, by Hox, ParaHox and microRNA genes). Numerous conserved noncoding elements (CNEs; often cis regulatory) undetectable in direct human-teleost comparisons become apparent using gar: functional studies uncovered conserved roles for such cryptic CNEs, facilitating annotation of sequences identified in human genome-wide association studies. Transcriptomic analyses showed that the sums of expression domains and expression levels for duplicated teleost genes often approximate the patterns and levels of expression for gar genes, consistent with subfunctionalization. The gar genome provides a resource for understanding evolution after genome duplication, the origin of vertebrate genomes and the function of human regulatory sequences

Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk

BRCA1-associated breast and ovarian cancer risks can be modified by common genetic variants. To identify further cancer risk-modifying loci, we performed a multi-stage GWAS of 11,705 BRCA1 carriers (of whom 5,920 were diagnosed with breast and 1,839 were diagnosed with ovarian cancer), with a further replication in an additional sample of 2,646 BRCA1 carriers. We identified a novel breast cancer risk modifier locus at 1q32 for BRCA1 carriers (rs2290854, P = 2.7×10-8, HR = 1.14, 95% CI: 1.09-1.20). In addition, we identified two novel ovarian cancer risk modifier loci: 17q21.31 (rs17631303, P = 1.4×10-8, HR = 1.27, 95% CI: 1.17-1.38) and 4q32.3 (rs4691139, P = 3.4×10-8, HR = 1.20, 95% CI: 1.17-1.38). The 4q32.3 locus was not associated with ovarian cancer risk in the general population or BRCA2 carriers, suggesting a BRCA1-specific associat

An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers

Introduction: Individuals carrying pathogenic mutations in the BRCA1 and BRCA2 genes have a high lifetime risk of breast cancer. BRCA1 and BRCA2 are involved in DNA double-strand break repair, DNA alterations that can be caused by exposure to reactive oxygen species, a main source of which are mitochondria. Mitochondrial genome variations affect electron transport chain efficiency and reactive oxygen species production. Individuals with different mitochondrial haplogroups differ in their metabolism and sensitivity to oxidative stress. Variability in mitochondrial genetic background can alter reactive oxygen species production, leading to cancer risk. In the present study, we tested the hypothesis that mitochondrial haplogroups modify breast cancer risk in BRCA1/2 mutation carriers. Methods: We genotyped 22,214 (11,421 affected, 10,793 unaffected) mutation carriers belonging to the Consortium of Investigators of Modifiers of BRCA1/2 for 129 mitochondrial polymorphisms using the iCOGS array. Haplogroup inference and association detection were performed using a phylogenetic approach. ALTree was applied to explore the reference mitochondrial evolutionary tree and detect subclades enriched in affected or unaffected individuals. Results: We discovered that subclade T1a1 was depleted in affected BRCA2 mutation carriers compared with the rest of clade T (hazard ratio (HR) = 0.55; 95% confidence interval (CI), 0.34 to 0.88; P = 0.01). Compared with the most frequent haplogroup in the general population (that is, H and T clades), the T1a1 haplogroup has a HR of 0.62 (95% CI, 0.40 to 0.95; P = 0.03). We also identified three potential susceptibility loci, including G13708A/rs28359178, which has demonstrated an inverse association with familial breast cancer risk. Conclusions: This study illustrates how original approaches such as the phylogeny-based method we used can empower classical molecular epidemiological studies aimed at identifying association or risk modification effects.Peer reviewe

Towards a Systematic Software Architecture for Acute Care Support

According to the Institute of Medicine (IOM) close to 100,000 safety-related medical incidents happens each year in US due to preventable medical errors. These preventable medical errors are caused by lack of timely and comprehensive information about the patient that makes the proper and efficient application of best available knowledge difficult rather than lack of such knowledge. The preventable medical errors often occur due to slips and lapses in settings where the staff are overloaded and under stress. Our focus is on acute care scenarios where medical staff must make quick decisions based on the best available evidence. In this paper, we propose an acute care support system (MACMS) that aids the physician with monitoring and making decisions given the best available knowledge to decrease preventable medical errors. Such a system is possible due to the opportunity presented to us by Medical Device Plug-and-Play (MDPnP) to integrate information from different devices in an integrated clinical environment. In this paper, we also present a model driven approach for designing these acute care support systems by developing models that correspond closely to medical mental processes and a system architecture to support execution from these models.unpublishe